Lantern Pharma Q2 2026: LP-300 PFS Deepens, EMA Clears LP-184, OMAI Spin-Off Formalized
LTRN has more than doubled off its 52-week low of $1.11.
Summary
Lantern Pharma reported Q2 2026 results with deepening LP-300 efficacy data, FDA and EMA regulatory progress, and the formal spin-off of its AI platform into Open Medicine AI, while cash remains tight at $7.4 million.
Key Events · Earnings and Guidance · LTRN
-
LP-300 PFS Benefit Deepens
Median progression-free survival reached 8.9 months in EGFR exon 21 L858R patients who completed six cycles of LP-300 (n=9), with a hazard ratio of 0.37 (95% CI 0.15–0.89) and a 77% clinical benefit rate.
-
FDA Clears Protocol Amendments
FDA reviewed without objection the Phase 2 HARMONIC trial amendments: enrollment concentrated on L858R patients, single-arm design, and maximum LP-300 treatment extended from six to eight cycles.
-
EMA Clears LP-184 Bladder Cancer Trial
EMA cleared an investigator-initiated Phase 1b/2 trial of LP-184 (zirdafulven) in advanced bladder cancer at Rigshospitalet, Denmark, using a dual biomarker strategy (PTGR1 overexpression plus DNA-damage repair deficiency).
-
Open Medicine AI Spin-Off Formalized
Open Medicine AI established as a separate company with board-approved commercial licensing agreements; OMAI is wholly owned by Lantern and intends to raise capital at the OMAI level, with a dedicated informational call planned for mid-September 2026.
Analysis · LTRN · Life Sciences
Lantern Pharma's Q2 2026 results pack multiple material updates: the HARMONIC trial's LP-300 shows a deepening progression-free survival benefit in EGFR exon 21 L858R lung cancer (median PFS 8.9 months, hazard ratio 0.37), the FDA cleared key protocol amendments without objection, and the EMA cleared an investigator-initiated Phase 1b/2 trial of LP-184 in bladder cancer. The company also formalized the spin-off of its AI platform into Open Medicine AI with board-approved commercial licenses and plans to raise capital at the OMAI level. Financially, cash stands at $7.4 million against a going concern warning, and the net loss of $7.1 million includes a $3.6 million non-cash warrant liability increase driven by the stock price rise — not operating deterioration. The operating loss actually fell 25% year over year to $3.5 million. This is a pivotal quarter for a micro-cap biotech balancing clinical momentum against a tight cash runway.
At the time of this filing, LTRN was trading at $2.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.6M. The 52-week trading range was $1.11 to $4.86. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.